Membrane drug transporters and chemoresistance in human pancreatic carcinoma

Cancers

Volumn 3, Issue 1, 2011, Pages 106-125

  Hagmann, Wolfgang ^a   Faissner, Ralf ^a   Schnölzer, Martina ^a   Löhr, Matthias ^a,b   Jesnowski, Ralf ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 fluorouracil; ABC transporters; Chemoresistance; Gemcitabine; Multidrug resistance proteins; Nucleoside transporters; OATPs; Pancreatic cancer; RNA interference; S100A4

Indexed keywords

ABC TRANSPORTER; CALVASCULIN; CELL PROTEIN; COMPLEMENTARY DNA; FLUOROURACIL; GEMCITABINE; MESSENGER RNA; MICRORNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NUCLEOSIDE; ORGANIC ANION TRANSPORTER; PROTEIN S 100;

CELL TRANSPORT; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CYTOTOXICITY TEST; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PHENOTYPE; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; RNA INTERFERENCE; TUMOR CELL;

EID: 79953701966     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010106     Document Type: Review

References (92)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. Lohr, M. Is it possible to survive pancreatic cancer? Nat. Clin. Pract. Gastroenterol Hepatol. 2006, 3, 236-237.
3. Merl, M.Y.; Abdelghany, O.; Li, J.; Saif, M.W. First-line treatment of metastatic pancreatic adenocarcinoma: Can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA, 4-8 June 2010, JOP 2010, 11, 317-320.
4. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
5. Hazlehurst, L.A.; Dalton, W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001, 20, 43-50.
6. Ghaneh, P.; Smith, R.; Tudor-Smith, C.; Raraty, M.; Neoptolemos, J.P. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur. J. Surg. Oncol. 2008, 34, 297-305.
7. Hilbig, A.; Oettle, H. Adjuvant therapy of pancreatic cancer. Expert. Rev. Anticancer Ther. 2010, 10, 485-491.
8. Mackey, J.R.; Mani, R.S.; Selner, M.; Mowles, D.; Young, J.D.; Belt, J.A.; Crawford, C.R.; Cass, C.E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998, 58, 4349-4357.
9. Mackey, J.R.; Yao, S.Y.; Smith, K.M.; Karpinski, E.; Baldwin, S.A.; Cass, C.E.; Young, J.D. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl. Cancer Inst. 1999, 91, 1876-1881.
10. Rius, M.; Keller, D.; Brom, M.; Hummel-Eisenbeiss, J.; Lyko, F.; Keppler, D. Vectorial transport of nucleoside analogs from the apical to the basolateral membrane in double-transfected cells expressing the human concentrative nucleoside transporter hCNT3 and the export pump ABCC4. Drug Metab. Dispos. 2010, 38, 1054-1063.
11. Ritzel, M.W.; Ng, A.M.; Yao, S.Y.; Graham, K.; Loewen, S.K.; Smith, K.M.; Hyde, R.J.; Karpinski, E.; Cass, C.E.; Baldwin, S.A.; Young, J.D. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: Identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol. 2001, 18, 65-72.
12. Andersson, R.; Aho, U.; Nilsson, B.I.; Peters, G.J.; Pastor-Anglada, M.; Rasch, W.; Sandvold, M.L. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scand. J. Gastroenterol. 2009, 44, 782-786.
13. Paproski, R.J.; Young, J.D.; Cass, C.E. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine. Biochem. Pharmacol. 2010, 79, 587-595.
14. Garcia-Manteiga, J.; Molina-Arcas, M.; Casado, F. J.; Mazo, A.; Pastor-Anglada, M. Nucleoside Transporter Profiles in Human Pancreatic Cancer Cells: Role of hCNT1 in 2',2'-Difluorodeoxycytidine-Induced Cytotoxicity. Clin. Cancer Res. 2003, 9, 5000-5008.
15. Marechal, R.; Mackey, J.R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C.E.; Young, J.; Salmon, I.; Deviere, J.; Van Laethem, J.L. Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma. Clin. Cancer Res. 2009, 15, 2913-2919.
16. Farrell, J.J.; Elsaleh, H.; Garcia, M.; Lai, R.; Ammar, A.; Regine, W.F.; Abrams, R.; Benson, A.B.; Macdonald, J.; Cass, C.E.; Dicker, A.F.; Mackey, J.R. Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer. Gastroenterology 2009, 136, 187-195.
17. Mini, E.; Nobili, S.; Caciagli, B.; Landini, I.; Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol. 2006, 17 (Suppl. 5), v7-v12.
18. Marechal, R.; Mackey, J.R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C.E.; Salmon, I.; Deviere, J.; Van Laethem, J.L. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010, 116, 5200-5206.
19. Ohhashi, S.; Ohuchida, K.; Mizumoto, K.; Fujita, H.; Egami, T.; Yu, J.; Toma, H.; Sadatomi, S.; Nagai, E.; Tanaka, M. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res. 2008, 28, 2205-2212.
20. Richards, N.G.; Rittenhouse, D.W.; Freydin, B.; Cozzitorto, J.A.; Grenda, D.; Rui, H.; Gonye, G.; Kennedy, E.P.; Yeo, C.J.; Brody, J.R.; Witkiewicz, A.K. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg. 2010, 252, 499-505; discussion 505-496.
21. Costantino, C.L.; Witkiewicz, A.K.; Kuwano, Y.; Cozzitorto, J.A.; Kennedy, E.P.; Dasgupta, A.; Keen, J.C.; Yeo, C.J.; Gorospe, M., Brody, J.R. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 2009, 69, 4567-4572.
22. Kruh, G.D.; Belinsky, M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22, 7537-7552.
23. Konig, J.; Nies, A.T.; Cui, Y.; Leier, I., Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophy. s Acta. 1999, 1461, 377-394.
24. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: The multidrug resistance-associated proteins. J. Natl. Cancer. Inst. 2000, 92, 1295-1302.
25. Borst, P.; de Wolf, C.; van de Wetering, K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers. Arch. 2007, 453, 661-673.
26. Hagmann, W.; Jesnowski, R.; Faissner, R.; Guo, C.; Lohr, J.M. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009, 9, 136-144.
27. Hagmann, W.; Jesnowski, R.; Lohr, J.M. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010, 12, 740-747.
28. Cui, Y.; Konig, J.; Buchholz, J.K.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 1999, 55, 929-937.
29. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237.
30. Zelcer, N.; Saeki, T.; Reid, G.; Beijnen, J.H.; Borst, P. Characterization of Drug Transport by the Human Multidrug Resistance protein 3 (ABCC3). J. Biol. Chem. 2001, 276, 46400-46407.
31. Pratt, S.; Shepard, R.L.; Kandasamy, R.A.; Johnston, P.A.; Perry, W.; 3rd, Dantzig, A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer. Ther. 2005, 4, 855-863.
32. Oguri, T.; Achiwa, H.; Sato, S.; Bessho, Y.; Takano, Y.; Miyazaki, M.; Muramatsu, H.; Maeda, H.; Niimi, T.; Ueda, R. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: A role of ABCC5 in gemcitabine sensitivity. Mol. Cancer Ther. 2006, 5, 1800-1806.
33. Kiuchi, Y.; Suzuki, H.; Hirohashi, T.; Tyson, C.A.; Sugiyama, Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998, 433, 149-152.
34. Konig, J.; Rost, D.; Cui, Y.; Keppler, D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999, 29, 1156-1163.
35. Kool, M.; van der Linden, M.; de Haas, M.; Scheffer, G.L.; de Vree, J.M.; Smith, A.J.; Jansen, G.; Peters, G.J.; Ponne, N.; Scheper, R.J.; Elferink, R.P.; Baas, F.; Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA 1999, 96, 6914-6919.
36. Scheffer, G.L.; Kool, M.; de Haas, M.; de Vree, J.M.; Pijnenborg, A.C.; Bosman, D.K.; Elferink, R.P.; van der Valk, P.; Borst, P.; Scheper, R.J. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 2002, 82, 193-201.
37. Konig, J.; Hartel, M., Nies, A.T.; Martignoni, M.E.; Guo, J.; Buchler, M.W.; Friess, H.; Keppler, D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer. 2005, 115, 359-367.
38. Nakano, Y.; Tanno, S.; Koizumi, K.; Nishikawa, T.; Nakamura, K.; Minoguchi, M.; Izawa, T.; Mizukami, Y.; Okumura, T.; Kohgo, Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 2007, 96, 457-463.
39. Rauchwerger, D.R.; Firby, P.S.; Hedley, D.W.; Moore, M.J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000, 60, 6075-6079.
40. Hong, S.P.; Wen, J.; Bang, S.; Park, S.; Song, S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009, 125, 2323-2331.
41. Hong, Y.B.; Kang, H.J.; Kwon, S.Y.; Kim, H.J.; Kwon, K.Y.; Cho, C.H.; Lee, J.M.; Kallakury, B.V.; Bae, I. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 2010, 39, 463-472.
42. Sims-Mourtada, J.; Izzo, J.G.; Ajani, J.; Chao, K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Onco gene 2007, 26, 5674-5679.
43. Chun, S.G.; Zhou, W.; Yee, N.S. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol. Ther. 2009, 8, 1328-1339.
44. Cui, D.; Xu, Q.; Wang, K.; Che, X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J. Neurol. Sci. 2010, 288, 156-166.
45. Queiroz, K.C.; Ruela-de-Sousa, R.R.; Fuhler, G.M.; Aberson, H.L.; Ferreira, C.V.; Peppelenbosch, M.P.; Spek, C.A. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010, [Epub ahead of print].
46. Santisteban, M. ABC Transporters as Molecular Effectors of Pancreatic Oncogenic Pathways: The Hedgehog-GLI Model. J. Gastrointest Cancer 2010, 41, 153-158.
47. Alvarez, A. I.; Real, R.; Perez, M.; Mendoza, G.; Prieto, J.G.; Merino, G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J. Pharm. Sci. 2010, 99, 598-617.
48. Borska, S.; Sopel, M.; Chmielewska, M.; Zabel, M.; Dziegiel, P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010, 15, 857-870.
49. Ma, J.; Dong, C.; Ji, C. MicroRNA and drug resistance. Cancer Gene Ther. 2010, 17, 523-531.
50. Giovannetti, E.; Funel, N.; Peters, G.J.; Del Chiaro, M.; Erozenci, L.A.; Vasile, E.; Leon, L.G.; Pollina, L.E.; Groen, A.; Falcone, A.; Danesi, R.; Campani, D.; Verheul, H.M.; Boggi, U. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70, 4528-4538.
51. Hwang, J. H.; Voortman, J.; Giovannetti, E.; Steinberg, S.M.; Leon, L.G.; Kim, Y.T.; Funel, N.; Park, J.K.; Kim, M.A.; Kang, G.H.; Kim, S.W.; Del Chiaro, M.; Peters, G.J.; Giaccone, G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5, e10630.
52. Wang, F.; Xue, X.; Wei, J.; An, Y.; Yao, J.; Cai, H.; Wu, J.; Dai, C.; Qian, Z.; Xu, Z.; Miao, Y. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br. J. Cancer 2010, 103, 567-574.
53. Haraguchi, N.; Utsunomiya, T.; Inoue, H.; Tanaka, F.; Mimori, K.; Barnard, G.F.; Mori, M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24, 506-513.
54. Yao, J.; Cai, H.H.; Wei, J.S.; An, Y.; Ji, Z.L.; Lu, Z.P.; Wu, J.L.; Chen, P.; Jiang, K.R.; Dai, C.C.; Qian, Z.Y.; Xu, Z.K.; Miao, Y. Side population in the pancreatic cancer cell lines SW 1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol. Rep. 2010, 23, 1375-1382.
55. Du, Z.; Qin, R.; Wei, C.; Wang, M.; Shi, C.; Tian, R.; Peng, C. Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in "Stem-Cell-Like" Tumor Cells. Dig. Dis. Sci. 2010, doi:10.1007/s10620-010-1340-0.
56. Lonardo, E.; Hermann, P.C.; Heeschen, C. Pancreatic cancer stem cells-update and future perspectives. Mol. Oncol. 2010, 4, 431-442.
57. Mueller, M. T.; Hermann, P.C.; Heeschen, C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci. (Elite Ed) 2010, 2, 602-613.
58. Rasheed, Z.A.; Yang, J.; Wang, Q.; Kowalski, J.; Freed, I.; Murter, C.; Hong, S.M.; Koorstra, J.B.; Rajeshkumar, N.V.; He, X.; Goggins, M.; Iacobuzio-Donahue, C.; Berman, D.M.; Laheru, D.; Jimeno, A.; Hidalgo, M.; Maitra, A.; Matsui, W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 2010, 102, 340-351.
59. Jonckheere, N.; Skrypek, N.; Van Seuningen, I. Mucins and Pancreatic Cancer. Cancers 2010, 2, 1794-1812.
60. Mimeault, M.; Johansson, S.L.; Senapati, S.; Momi, N.; Chakraborty, S.; Batra, S.K. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 2010, 295, 69-84.
61. Hagenbuch, B.; Meier, P.J. Organic anion transporting polypeptides of the OATP/ SLC21 family: Phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004, 447, 653-665.
62. Konig, J.; Cui, Y.; Nies, A.T.; Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 2000, 275, 23161-23168.
63. Konig, J.; Cui, Y.; Nies, A.T.; Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest Liver Physiol. 2000, 278, G156-G164.
64. Hagenbuch, B.; Meier, P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 2003, 1609, 1-18.
65. Tamai, I.; Nezu, J.; Uchino, H.; Sai, Y.; Oku, A.; Shimane, M.; Tsuji, A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 2000, 273, 251-260.
66. Jesnowski, R.; Backhaus, C.; Ringel, J.; Lohr, M. Ribosomal highly basic 23-kDa protein as a reliable standard for gene expression analysis. Pancreatology 2002, 2, 421-424.
67. Jesnowski, R.; Furst, D.; Ringel, J.; Chen, Y.; Schrodel, A.; Kleeff, J.; Kolb, A.; Schareck, W.D., Lohr, M. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: Deactivation is induced by matrigel and N-acetylcysteine. Lab Invest. 2005, 85, 1276-1291.
68. Haber, P.S.; Keogh, G.W.; Apte, M.V.; Moran, C.S.; Stewart, N.L.; Crawford, D.H.; Pirola, R.C.; McCaughan, G.W.; Ramm, G.A.; Wilson, J.S. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am. J. Pathol. 1999, 155, 1087-1095.
69. Yen, T.W.; Aardal, N.P.; Bronner, M.P.; Thorning, D.R.; Savard, C.E.; Lee, S.P.; Bell, R.H., Jr. Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 2002, 131, 129-134.
70. Schneiderhan, W.; Diaz, F.; Fundel, M.; Zhou, S.; Siech, M.; Hasel, C.; Moller, P.; Gschwend, J.E.; Seufferlein, T.; Gress, T.; Adler, G.; Bachem, M.G. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J. Cell Sci. 2007, 120, 512-519.
71. Xu, Z.; Vonlaufen, A.; Phillips, P.A.; Fiala-Beer, E.; Zhang, X.; Yang, L.; Biankin, A.V.; Goldstein, D.; Pirola, R.C.; Wilson, J.S.; Apte, M.V. Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis. Am. J. Pathol. 2010, 177, 2585-2596.
72. Shi, X.; Liu, S.; Kleeff, J.; Friess, H.; Buchler, M.W. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosisregulating genes. Oncology 2002, 62, 354-362.
73. Monti, P.; Marchesi, F.; Reni, M.; Mercalli, A.; Sordi, V.; Zerbi, A.; Balzano, G.; Di Carlo, V.; Allavena, P.; Piemonti, L. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 2004, 445, 236-247.
74. Faissner, R. Clinical Cooperation Unit of Molecular Gastroenterology, German Cancer Research Center, Heidelberg, Germany, unpublished data, 2010.
75. Oguri, T.; Bessho, Y.; Achiwa, H.; Ozasa, H.; Maeno, K.; Maeda, H.; Sato, S.; Ueda, R. MRP8/ABCC1 1 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 2007, 6, 122-127.
76. Nambaru, P.K.; Hubner, T.; Kock, K.; Mews, S.; Sendler, M.; Grube, M.; Payen, L.; Guitton, J.; Jedlitschky, G.; Rimmbach, C.; Rosskopf, D.; Kowalczyk, D.W.; Kroemer, H.K.; Weiss, F.U.; Mayerle, J.; Lerch, M.M., Ritter, C.A. Drug efflux transporter MRP5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos 2010, 39, 132-139.
77. Kikuchi, N.; Horiuchi, A.; Osada, R.; Imai, T.; Wang, C.; Chen, X.; Konishi, I. Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: An important autocrine/paracrine factor in tumor progression. Cancer Sci. 2006, 97, 1061-1069.
78. Fernandez-Fernandez, M.R.; Veprintsev, D.B.; Fersht, A.R. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc. Natl. Acad. Sci. USA 2005, 102, 4735-4740.
79. Cabezon, T.; Celis, J.E.; Skibshoj, I.; Klingelhofer, J.; Grigorian, M.; Gromov, P.; Rank, F.; Myklebust, J.H.; Maelandsmo, G.M. Lukanidin, E., Ambartsumian, N. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int. J. Cancer 2007, 121, 1433-1444.
80. Mahon, P.C.; Baril, P.; Bhakta, V.; Chelala, C.; Caulee, K.; Harada, T.; Lemoine, N.R. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 2007, 67, 6786-6795.
81. Kulke, M.H. Advanced pancreatic cancer: Is there a role for combination therapy? Expert Rev. Anticancer Ther. 2003, 3, 729-739.
82. El-Rayes, B.F.; Philip, P.A. Systemic therapy for advanced pancreatic cancer. Expert Rev. Anticancer Ther. 2002, 2, 426-436.
83. Heinemann, V.; Boeck, S.; Hinke, A.; Labianca, R.; Louvet, C. Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8, 82.
84. Tsujie, M.; Nakamori, S.; Nakahira, S.; Takeda, S.; Takahashi, Y.; Hayashi, N.; Okami, J.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Monden, M. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas 2006, 33, 142-147.
85. Pressacco, J.; Mitrovski, B.; Erlichman, C.; Hedley, D.W. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995, 55, 1505-1508.
86. Reid, G.; Wielinga, P.; Zelcer, N.; De Haas, M.; Van Deemter, L.; Wijnholds, J.; Balzarini, J.; Borst, P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 2003, 63, 1094-1103.
87. Sipos, B.; Moser, S.; Kalthoff, H.; Torok, V.; Lohr, M.; Kloppel, G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Arch. 2003, 442, 444-452.
88. Lohr, J.M.; Faissner, R.; Koczan, D.; Bewerunge, P.; Bassi, C., Brors, B.; Eils, R.; Frulloni, L.; Funk, A.; Halangk, W.; Jesnowski, R.; Kaderali, L.; Kleeff, J.; Kruger, B.; Lerch, M.M.; Losel, R.; Magnani, M.; Neumaier, M.; Nittka, S.; Sahin-Toth, M.; Sanger, J.; Serafini, S.; Schnolzer, M.; Thierse, H.J.; Wandschneider, S.; Zamboni, G.; Kloppel, G. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: Gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am. J. Gastroenterol. 2010, 105, 2060-2071.
89. Schutt, F.; Ueberle, B.; Schnolzer, M.; Holz, F.G.; Kopitz, J. Proteome analysis of lipofuscin in human retinal pigment epithelial cells. FEBS. Lett. 2002, 528, 217-221.
90. Shain, K.H.; Yarde, D.N.; Meads, M.B.; Huang, M.; Jove, R.; Hazlehurst, L.A.; Dalton, W.S. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: Implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009, 69, 1009-1015.
91. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M.A.; Caldwell, M.E.; Allard, D.; Frese, K.K.; Denicola, G.; Feig, C.; Combs, C.; Winter, S.P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W.J.; Chang, A.; Dhara, M.; Wang, L.; Ruckert, F.; Grutzmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S.R.; Huang, P.; Davies, S.E.; Plunkett, W.; Egorin, M.; Hruban, R.H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324, 1457-1461.
92. Habisch, H.; Zhou, S.; Siech, M., Bachem, M.G. Interaction of Stellate Cells with Pancreatic Carcinoma Cells. Cancers 2010, 2, 1661-1682.